BioNTech SE (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

BioNTech SE (NASDAQ:BNTX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eighteen ratings firms that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, fourteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $143.44.

Several research firms have commented on BNTX. Morgan Stanley decreased their price objective on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. BMO Capital Markets increased their price target on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Truist Financial started coverage on BioNTech in a research report on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective on the stock. Citigroup initiated coverage on BioNTech in a research note on Thursday, March 13th. They issued a "buy" rating and a $145.00 price objective for the company. Finally, HC Wainwright cut their price target on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st.

BioNTech Trading Down 15.4 %

BNTX opened at $102.02 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company's 50-day moving average is $101.72 and its 200 day moving average is $110.64. The firm has a market capitalization of $24.48 billion, a PE ratio of -48.58 and a beta of 1.07. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech's quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.90 earnings per share. As a group, research analysts predict that BioNTech will post -3.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jones Financial Companies Lllp grew its stake in BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after acquiring an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. boosted its stake in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after buying an additional 700 shares during the period. Allianz SE purchased a new position in BioNTech during the fourth quarter worth about $90,000. GAMMA Investing LLC increased its position in shares of BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company's stock worth $105,000 after purchasing an additional 300 shares during the last quarter. Finally, Goodman Advisory Group LLC bought a new stake in shares of BioNTech during the 1st quarter worth $105,000. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.